Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).

ABSTRACT: Gastric cancer (GC) has a high global incidence and mortality rate [...].

SUBMITTER: Zheng B 

PROVIDER: S-EPMC11852535 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature